Technical Analysis for ELEV - Elevation Oncology, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 4.20 | 18.31% | 0.65 |
ELEV closed down 7.79 percent on Tuesday, April 30, 2024, on 2.0 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: May 2
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 180 Bearish Setup | Bearish Swing Setup | 18.31% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 18.31% | |
| Wide Bands | Range Expansion | 18.31% | |
| Oversold Stochastic | Weakness | 18.31% | |
| Outside Day | Range Expansion | 9.09% | |
| Wide Bands | Range Expansion | 9.09% | |
| Oversold Stochastic | Weakness | 9.09% | |
| Inside Day | Range Contraction | 16.02% | |
| Wide Bands | Range Expansion | 16.02% | |
| Down 3 Days in a Row | Weakness | 16.02% |
| Alert | Time |
|---|---|
| Possible Pocket Pivot | about 2 hours ago |
| Rose Above 20 DMA | about 2 hours ago |
| Rose Above 50 DMA | about 2 hours ago |
| Up 2 ATRs | about 2 hours ago |
| 50 DMA Resistance | about 2 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/02/2024
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically-defined patient populations in the United States. Its lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. The company was incorporated in 2019 and is based in New York, New York.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Clinical Medicine Life Sciences Immunology Health Sciences Pharmacy Treatment Of Cancer Monoclonal Antibody Advanced Solid Tumors Duligotuzumab
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Clinical Medicine Life Sciences Immunology Health Sciences Pharmacy Treatment Of Cancer Monoclonal Antibody Advanced Solid Tumors Duligotuzumab
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 5.89 |
| 52 Week Low | 0.363 |
| Average Volume | 1,021,308 |
| 200-Day Moving Average | 1.89 |
| 50-Day Moving Average | 4.27 |
| 20-Day Moving Average | 4.32 |
| 10-Day Moving Average | 3.89 |
| Average True Range | 0.41 |
| RSI (14) | 37.89 |
| ADX | 24.79 |
| +DI | 18.90 |
| -DI | 22.18 |
| Chandelier Exit (Long, 3 ATRs) | 4.59 |
| Chandelier Exit (Short, 3 ATRs) | 4.70 |
| Upper Bollinger Bands | 5.32 |
| Lower Bollinger Band | 3.33 |
| Percent B (%b) | 0.11 |
| BandWidth | 46.02 |
| MACD Line | -0.20 |
| MACD Signal Line | -0.09 |
| MACD Histogram | -0.1124 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.32 | ||||
| Resistance 3 (R3) | 4.40 | 4.23 | 4.19 | ||
| Resistance 2 (R2) | 4.23 | 4.04 | 4.19 | 4.14 | |
| Resistance 1 (R1) | 3.89 | 3.91 | 3.81 | 3.81 | 4.10 |
| Pivot Point | 3.72 | 3.72 | 3.68 | 3.68 | 3.72 |
| Support 1 (S1) | 3.38 | 3.53 | 3.30 | 3.30 | 3.00 |
| Support 2 (S2) | 3.21 | 3.40 | 3.17 | 2.96 | |
| Support 3 (S3) | 2.87 | 3.21 | 2.91 | ||
| Support 4 (S4) | 2.79 |
